The number of cancer cases in the UK has reached an unprecedented level, with more than 403,000 new diagnoses each year – the equivalent of one diagnosis every 80 seconds. According to a new report from Cancer Research UK, this rise is being driven primarily by an ageing and growing population, alongside persistent risk factors such as obesity.
Incidence rates have increased to 620 cases per 100,000 people, up from 610 a decade ago and around 15% higher than in the early 1990s. While this reflects demographic shifts, it also underscores broader public health challenges that continue to shape long-term demand on the system.
Chief Executive of Cancer Research UK, Michelle Mitchell said:
“More people are being diagnosed with cancer than ever before. Although cancer survival has doubled since the 1970s, progress has slowed over the last decade.”
Progress at risk as survival gains begin to stall
Despite improvements in survival rates over recent decades, there are growing concerns that progress may now plateau. Advances in treatment and earlier detection have led to more people living longer after diagnosis, but the pace of improvement has slowed significantly.
Mitchell warned that while the Government’s National Cancer Plan represents an important step forward, it is far from sufficient on its own.
“The Government’s recently published National Cancer Plan could make a big difference, but only if it turns into improvements for cancer patients,” she said.
This reflects a wider concern across the sector: that policy announcements are not consistently translating into operational delivery at the frontline of care.
Early diagnosis remains stubbornly unchanged
One of the most persistent challenges is the limited progress in early diagnosis. Just over half of cancer cases in the UK are identified at an early stage – a figure that has barely shifted in recent years, rising only marginally from 54% to 55%.
For a condition where early detection is strongly linked to survival outcomes, this stagnation is significant. Cancer Research UK has called for the rapid expansion of screening programmes, particularly lung cancer screening, which could detect up to 7,800 additional cases annually if fully optimised across England.
The organisation has also urged faster rollout of innovative diagnostic technologies, arguing that these tools are essential to closing the gap between detection and treatment.
Commenting on the report, Chief Executive of BIVDA, Helen Dent said “The adoption of diagnostics is critical in improving outcomes for patients and as well as innovative diagnostics being implemented quickly, there are diagnostics available now that have not been adopted adequately which could make a difference to people immediately.
“Screening and early detection is a tool that is not being effectively utilised across the UK especially in communities which have challenges in accessing healthcare.”
NHS capacity constraints intensify cancer cases pressure
Alongside rising demand, the NHS continues to face sustained operational strain. Waiting times for cancer treatment are now among the worst on record, with around 107,000 patients waiting more than 62 days to begin treatment in 2025.
This backlog highlights the widening gap between diagnosis and intervention – a gap that has direct implications for patient outcomes.
A spokesperson for the Department of Health and Social Care acknowledged the pressure but pointed to recent investment and progress:
“We have delivered a record number of diagnostic tests in the last 12 months, backed by an extra £26 billion for the NHS – and the number of patients getting a cancer diagnosis or all-clear on time is the highest in five years – but we are not complacent.”
The Government’s plan aims for 75% of patients diagnosed from 2035 to be cancer-free or living well after five years, alongside commitments to faster diagnosis and improved treatment pathways.
Representing innovators in the UK healthcare and life sciences sectors, CEO of UK Healthcare and Life Sciences Innovation (UKHLSI), Joanne Bekis said: “As cancer diagnoses rise, the UK’s strength in life sciences innovation must now translate into preventative and faster adoption of diagnostics and treatments across the health system.”
Prevention, policy, and the growing role of obesity
Alongside pressures on treatment capacity, prevention is emerging as an increasingly urgent priority. Cancer Research UK has stressed the importance of fully implementing the forthcoming Tobacco and Vapes Bill, which will prohibit smoking for those born after 2008, as a critical step in reducing future cancer risk.
However, smoking is no longer the only dominant driver. Obesity is now one of the leading causes of cancer in the UK, contributing to rising incidence across multiple cancer types. With obesity rates continuing to climb, the long-term burden on the health system is set to increase unless prevention strategies are broadened beyond tobacco control to address diet, lifestyle, and wider determinants of health.
The charity warns that without decisive, system-wide action on prevention, cancer incidence will continue its upward trajectory, placing further strain on already stretched NHS services.
At the same time, calls for increased investment in specialist staff and equipment point to a deeper structural challenge – ensuring that workforce capacity and infrastructure evolve in step with both rising patient demand and advances in diagnostics and treatment.
Curia’s Health, Care, and Life Sciences Research Group Advisory Board member, and former National Deputy Medical Director at NHS England, Professor Mike Bewick said “Rising cancer demand is exposing the gap between diagnosis and treatment – and that is where the system must now focus.”
A system challenge, not just a clinical one
Taken together, the data presents a clear picture that the UK is not facing a shortage of innovation or policy intent, but a growing challenge in translating both into consistent, system-wide delivery.
The convergence of rising diagnoses, constrained capacity, and uneven progress on early detection points to a structural issue within the health system. Without coordinated investment, workforce expansion, and accelerated adoption of diagnostics and screening, there is a risk that decades of progress in cancer outcomes could begin to reverse.
As Mitchell’s warning suggests, the next phase of cancer policy will be defined by delivery on their promises.
Get Involved
To find out more about Curia’s Obesity Summit and work to improve cancer outcomes, please contact Partnerships Director, Ben McDermott at ben.mcdermott@chamberuk.com.